Groupe d'Etude en Oncologie du Quebec

Title	Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study
Protocole ID	A14-11-2181
ClinicalTrials.gov ID	NCT02754297
Cancer Type(s)	Neuroendocrine tumors
Phase	Phase II
Stage
Study Type
Drug
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL L'HOTEL-DIEU DE QUEBEC ET CRCEO 11 Côte du Palais, Québec, QC, G1R 2J6
City	Québec
Principal Investigator	Dr. Jean-Mathieu Beauregard
Coordinator	Guillaume Bouvet 418-525-4444
Status	Recruiting
Activation Date
Eligibility Criteria	Patient suffering from a progressive and/or symptomatic NET (any site); Patient ineligible to, or refusing a potentially curative treatment such as surgical resection; Patient who did not respond, is intolerant or refuses other indicated and available palliative treatments; Demonstration of overexpression of somatostatin receptor by tumor lesions by scintigraphic imaging (Octreoscan or 68Ga positron emission tomography.
Exclusion Criteria	Pregnancy; Breastfeeding;. Very limited survival prognosis (i.e. less than a few weeks, because of the NET disease or any other condition) or Eastern Cooperative Oncology Group (ECOG) 4 performance status; Inability to obtain informed consent of the participant.

Groupe d'étude en oncologie du Québec